Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956129 | 1.00 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1LIPEKDM4ESCN8A | |
| SCHEMBL9751833 | 0.84 | SCN8A (0.41) | L3MBTL1ALDH1A1SCN8ALMNAMEN1 | |
| SCHEMBL1547887 | 0.82 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL30254552 | 0.81 | SCN4A (0.44) | ALDH1A1KDM4ESCN8ALMNAGAA | |
| SCHEMBL29954624 | 0.81 | LIPE (0.33) | LIPESCN8AENPP2 | |
| SCHEMBL23210246 | 0.80 | LIPE (0.58) | L3MBTL1LIPELMNAENPP2NPC1 | |
| SCHEMBL29691238 | 0.80 | LIPE (0.58) | L3MBTL1LIPELMNAENPP2NPC1 | |
| SCHEMBL3790469 | 0.79 | LIPE (0.44) | L3MBTL1ALDH1A1LIPEKDM4ELMNA | |
| SCHEMBL13696460 | 0.79 | ACHE (0.44) | L3MBTL1KDM4ESCN8ALMNA | |
| SCHEMBL5198 | 0.79 | ENPP2 (0.47) | ALDH1A1KDM4ESMN1; SMN2ENPP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| EP-3883570-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-9376436-B2 | 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators | Convergence Pharmaceuticals Limited (GB) | 2016-06-28 | — | — | US | disclosed |
| EP-2794612-B1 | 2-(PYRIDIN-2YL)-1,7-DIAZA-SPIRO[4.4]NONANE-6-ONE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885ALDH1A1 2352/4885LIPE 4333/4885 |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | SCN1A, SCN2A, SCN1B | L3MBTL1 4624/4885ALDH1A1 705/4885LIPE 4613/4885 |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885ALDH1A1 2352/4885LIPE 4333/4885 |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885ALDH1A1 2352/4885LIPE 4333/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885ALDH1A1 2352/4885LIPE 4333/4885 |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885ALDH1A1 2352/4885LIPE 4333/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885ALDH1A1 2352/4885LIPE 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.